Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CDA | P32320 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7870020 | 0.88 | KDM4E (0.37) | KDM4EGAAPOLBALDH1A1TP53 | |
| SCHEMBL2851485 | 0.81 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL11669907 | 0.80 | TP53 (0.32) | KDM4EGAAPOLBALDH1A1TP53 | |
| SCHEMBL5904175 | 0.79 | CRBN (0.37) | KDM4EGAAPOLBALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL11671580 | 0.79 | TP53 (0.32) | KDM4EGAAPOLBALDH1A1TP53 | |
| SCHEMBL10772828 | 0.77 | — | — | |
| SCHEMBL4500931 | 0.77 | GAA (0.35) | GAAALDH1A1 | |
| SCHEMBL146124 | 0.73 | — | — | |
| SCHEMBL1971796 | 0.73 | CDA (0.33) | KDM4ECDA | |
| SCHEMBL4063011 | 0.71 | KDM4E (0.33) | KDM4EGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0083315-B1 | PYRIDYL-N-OXIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1987-07-29 | — | — | EP | claimed |
| CN-113717168-A | Synthesis method of piperidino-dihydroimidazolone formic acid | 江苏弘和药物研发有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-101796055-B | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2013-09-04 | — | — | CN | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| CN-101796055-A | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2010-08-04 | — | — | CN | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1957498-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | MethylGene Inc. (CA) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-0083315-B1 | PYRIDYL-N-OXIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | KDM4E 2703/4885GAA 1261/4885POLB 2628/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | KDM4E 4094/4885GAA 1146/4885POLB 1325/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | KDM4E 4651/4885GAA 2532/4885POLB 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.